# Sunitinib as First-Line Therapy in Treating Patients With Locally Advanced Metastatic Papillary Renal Cell Cancer

> **NCT00541008** · PHASE2 · COMPLETED · sponsor: **UNICANCER** · enrollment: 92 (actual)

## Conditions studied

- Kidney Cancer

## Interventions

- **DRUG:** sunitinib malate

## Key facts

- **NCT ID:** NCT00541008
- **Lead sponsor:** UNICANCER
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-09-05
- **Primary completion:** 2011-02
- **Final completion:** 2013-04
- **Target enrollment:** 92 (ACTUAL)
- **Last updated:** 2021-02-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00541008

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00541008, "Sunitinib as First-Line Therapy in Treating Patients With Locally Advanced Metastatic Papillary Renal Cell Cancer". Retrieved via AI Analytics 2026-08-01 from https://api.ai-analytics.org/clinical/NCT00541008. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*